API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Norepinephrine Bitartrate is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension.
Lead Product(s): Norepinephrine Bitartrate,Dextrose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Under the agreement, Long Grove Pharmaceuticals in-licensed Norepinephrine Bitartrate in 0.9% Sodium Chloride premix formulation, indicated to raise blood pressure in adult patients with severe, acute hypotension, from Nevakar Injectables.
Lead Product(s): Norepinephrine Bitartrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: NVK004
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Long Grove Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2023